ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
General Health & Fitness
Workouts & Routines
Powerful hormone jab could get elderly exercising 'like they were years younger'
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 50730" data-attributes="member: 3"><p><strong>Serum Osteocalcin Levels Correlate with Hypogonadal Symptoms in Men: Implications for the Use of Osteocalcin as a Marker for Hypogonadism</strong></p><p></p><p><strong>American Urological Association conference</strong></p><p></p><p></p><p></p><p>Abstract: 806</p><p>Date & Time: May 21, 2012 08:00 AM</p><p>Session Title: Sexual Function/Dysfunction/Andrology: Basic Research I</p><p>Sources of Funding: None</p><p></p><p>Introduction and Objectives</p><p>Osteocalcin is secreted by osteoblasts and is a marker of bone formation. In addition, recent work implicates osteocalcin as a regulator of testosterone (T) production through its stimulation of Leydig cells, potentially implicating osteocalcin in hypogonadism. The diagnosis of hypogonadism currently relies on evaluation of serum T and free T levels, as well as hypogonadal symptoms. However, the role of osteocalcin as a possible marker for hypogonadism is unclear. Here we evaluate the association between serum osteocalcin levels and the symptoms of hypogonadism.</p><p></p><p>Methods</p><p>A review of 54 men presenting to our clinic was performed, and demographic information, testosterone (T) and osteocalcin levels were obtained for each patient. All patients completed the quantitative Androgen Decline in the Aging Male (qADAM) questionnaire, a metric for the evaluation of hypogonadal symptoms, and responses were correlated to osteocalcin levels using Spearman’s rank correlation.</p><p></p><p>Results</p><p>Mean±SD subject age was 51.1±11.6 years, serum T 398.4±190.2 ng/dL, and osteocalcin 5.35±3.33 ng/mL. Significant negative correlations were observed between osteocalcin and total qADAM score (ρ=-0.422, p=0.002), as well as individual qADAM questions including energy level (ρ=-0.304, p=0.025), strength endurance rating (ρ=-0.349, p=0.01), enjoyment of life (ρ=-0.299 p=0.028) and happiness (ρ=-0.391, p=0.004) ratings, and work performance over the last 4 weeks (ρ=-0.319, p=0.019). We then separated men by total qADAM score into 0-20 (severe hypogonadism), 21-30 (moderate hypogonadism), and >30 (minimal or no hypogonadism) and observed a significant difference between osteocalcin levels in the 0-20 (mean±SD osteocalcin 6.3±3.5 ng/mL) and >30 groups (osteocalcin 2.2±1.8 ng/mL, p=0.03). No significant differences in serum testosterone were observed in any subgroup, and no impact on qADAM score or osteocalcin level was observed as a function of whether men were on testosterone replacement therapy.</p><p></p><p>Conclusions</p><p>Serum osteocalcin levels are inversely correlated with hypogonadal symptoms assessed using the qADAM questionnaire, suggesting that osteocalcin may be a useful marker for hypogonadism. Future work to further validate these conclusions, in the form of more extensive evaluation of the interplay of serum and symptomatic parameters, as well as concomitant evaluation of bone health, will further elucidate the utility of osteocalcin as a serum marker for hypogonadism.</p><p></p><p>Authors</p><p>Pastuszak, Alexander W. (Houston, TX); Badhiwala, Niraj; Song, Weitao; Lamb, Dolores J.; Lipshultz, Larry I.; Khera, Mohit</p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 50730, member: 3"] [B]Serum Osteocalcin Levels Correlate with Hypogonadal Symptoms in Men: Implications for the Use of Osteocalcin as a Marker for Hypogonadism[/B] [B][FONT=FrutigerNeueW01-Regular]American Urological Association conference[/FONT][/B] Abstract: 806 Date & Time: May 21, 2012 08:00 AM Session Title: Sexual Function/Dysfunction/Andrology: Basic Research I Sources of Funding: None Introduction and Objectives Osteocalcin is secreted by osteoblasts and is a marker of bone formation. In addition, recent work implicates osteocalcin as a regulator of testosterone (T) production through its stimulation of Leydig cells, potentially implicating osteocalcin in hypogonadism. The diagnosis of hypogonadism currently relies on evaluation of serum T and free T levels, as well as hypogonadal symptoms. However, the role of osteocalcin as a possible marker for hypogonadism is unclear. Here we evaluate the association between serum osteocalcin levels and the symptoms of hypogonadism. Methods A review of 54 men presenting to our clinic was performed, and demographic information, testosterone (T) and osteocalcin levels were obtained for each patient. All patients completed the quantitative Androgen Decline in the Aging Male (qADAM) questionnaire, a metric for the evaluation of hypogonadal symptoms, and responses were correlated to osteocalcin levels using Spearman’s rank correlation. Results Mean±SD subject age was 51.1±11.6 years, serum T 398.4±190.2 ng/dL, and osteocalcin 5.35±3.33 ng/mL. Significant negative correlations were observed between osteocalcin and total qADAM score (ρ=-0.422, p=0.002), as well as individual qADAM questions including energy level (ρ=-0.304, p=0.025), strength endurance rating (ρ=-0.349, p=0.01), enjoyment of life (ρ=-0.299 p=0.028) and happiness (ρ=-0.391, p=0.004) ratings, and work performance over the last 4 weeks (ρ=-0.319, p=0.019). We then separated men by total qADAM score into 0-20 (severe hypogonadism), 21-30 (moderate hypogonadism), and >30 (minimal or no hypogonadism) and observed a significant difference between osteocalcin levels in the 0-20 (mean±SD osteocalcin 6.3±3.5 ng/mL) and >30 groups (osteocalcin 2.2±1.8 ng/mL, p=0.03). No significant differences in serum testosterone were observed in any subgroup, and no impact on qADAM score or osteocalcin level was observed as a function of whether men were on testosterone replacement therapy. Conclusions Serum osteocalcin levels are inversely correlated with hypogonadal symptoms assessed using the qADAM questionnaire, suggesting that osteocalcin may be a useful marker for hypogonadism. Future work to further validate these conclusions, in the form of more extensive evaluation of the interplay of serum and symptomatic parameters, as well as concomitant evaluation of bone health, will further elucidate the utility of osteocalcin as a serum marker for hypogonadism. Authors Pastuszak, Alexander W. (Houston, TX); Badhiwala, Niraj; Song, Weitao; Lamb, Dolores J.; Lipshultz, Larry I.; Khera, Mohit [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
General Health & Fitness
Workouts & Routines
Powerful hormone jab could get elderly exercising 'like they were years younger'
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top